Clinical
Treatment developments for metastatic castration-resistant prostate cancer
Radium-223 (Ra-223) dichloride is the first bone-targeted therapy for men with metastatic castration-resistant prostate cancer (mCRPC) with the ability to improve quality of life and overall survival, and the additional advantage of a good safety profile. Ra-223 is administered as an intravenous injection and since the radioactivity is low, it can be given on an outpatient basis with appropriate radiation protection procedures.
As Ra-223 has the potential to play a significant role in management of men with mCRPC, it is important to establish appropriate protocols and procedures to accommodate its use in standard clinical practice.
